June 27, 2014

RE: Prior Authorization of Sovaldi™, Olysio™, Victrelis®, and Incivek® for the treatment of Hepatitis C

Dear Pharmacist,

The Oklahoma Health Care Authority (OHCA) anticipates that a Prior Authorization requirement will be implemented July 1, 2014 for coverage of Sovaldi™, Olysio™, Victrelis®, and Incivek® for the treatment of Hepatitis C.

The PA criteria for these medications can be found at www.okhca.org/pa. Click on the link that says “Hepatitis C.”

Due to the nature of the treatment regimen and expense, additional documentation is required before authorization will be granted. For each new start, please submit the

- Treatment Initiation Prior Authorization Form
  - Sovaldi™ (PHARM-26); or
  - Olysio™ (PHARM-27)
- Patient Consent and Intent to Treat Contract (PHARM-28)
- Pharmacy Agreement (PHARM-29)

A Continuation of Therapy Form (PHARM-30) is required with each refill to assure the patient is adhering to the prescribed regimen. These forms are required for all patients refilling one of these medications after July 1, 2014. These forms can all be found at www.okhca.org/rx-forms.

SoonerCare records indicate your pharmacy NPI has been listed on paid claims for one of these medications (Sovaldi™, Olysio™, Victrelis®, and Incivek®). Any new patient that plans to start on these medications will need the above forms, and any patient who has not completed therapy with these medications will need a Continuation of Therapy Form for their refills to be approved.

If you have any questions please contact the pharmacy help desk at (800) 522-0114, option 4.

Thank you for your continued service to Oklahoma’s SoonerCare members.
Hepatitis C Therapy Continuation Prior Authorization Form

Member Name: __________________________ Date of Birth: __________ Member ID#: __________
Pharmacy Name: __________________________ Pharmacy NPI: __________________________
Pharmacy Phone: __________________________ Pharmacy Fax: __________________________
Pharmacist Name: __________________________ Prescriber Name: __________________________
Prescriber NPI: __________________________ Specialty: __________________________
Prescriber Phone: __________________________ Prescriber Fax: __________________________

Pharmacy Section

Member’s Hepatitis C Therapy Regimen:

__________________________________________________________

Drug Name: ___________________________________________ NDC: __________________________

Today’s Date: __________________________ Date Prescription Last Filled: ______________________
Date Member Took First Dose: __________________________ Expected End Date: ______________

Number of doses remaining today: ___________ Refill Number: __________________________

Did the member fill pegylated interferon?  Yes____ No_____
Date pegylated interferon last filled: _______________ Remaining Supply: __________________

Did the member fill ribavirin?  Yes____ No_____
Date ribavirin last filled: _______________ Remaining Supply: __________________________

Pharmacist Signature: __________________________ Date: __________________________

Prescriber Section

Initial Viral Load: __________________________ Date Tested: __________________________
Recent Viral Load: __________________________ Date Tested: __________________________
Recent Urine Drug Screen?  Yes____ No____  Date Tested: __________________________
Monthly Pregnancy Test?**  Yes____ No____ NA____ Date Tested: __________________________
**Required for female members and female partners of male members.

Has the member experience any adverse drug reactions related to hepatitis C therapy?
Yes____ No____
If yes, please specify reactions: ______________________________________________________
__________________________________________________________________________________

Prescriber Signature: __________________________ Date: __________________________

Please do not send in chart notes. Specific information/documentation will be requested if necessary.

Please provide the information requested and return to:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

Confidentiality Notice

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Approved 06-18-14